ABSTRACT
Introduction
Systemic sclerosis (SSc, scleroderma) is a complex disorder including varying degrees of vascular occlusion, tissue fibrosis and inflammation (1) . Although around 80% of those diagnosed with SSc are women (1) , most of the studies on the effect of SSc on sexual functioning have involved men (2) (3) (4) (5) (6) . Male erectile dysfunction has been noted in as many as 80% of afflicted persons and is attributed to scleroderma vasculopathy although cavernosal fibrosis may play a role in some patients (2, 3) . Little is known of the impact of scleroderma on female sexual functioning and on quality of female sex life. We conducted an investigation on the patient-reported impact on sexual functioning among female SSc patients. Existing research suggests that physical changes associated with SSc can have a negative impact on female sexuality and sexual functioning. Skin tightening around the vaginal introitus, joint contractures, muscle weakness, changes in skin around the breasts and breast muscle, and joint pain are frequently mentioned as symptoms associated with lower levels of sexual functioning, desire, arousal, lubrication, and satisfaction in female SSc patients (2, 4, 6) . Changes in the vaginal mucosal may lead to difficulties with lubrication. These symptoms can hinder sexual enjoyment for SSc patients as well as cause their sexual partners to be reluctant to engage in sexual activity due to the fear of causing pain or discomfort to the person with SSc. There are many other issues that can also impact sexuality and sexual functioning among women with SSc. For instance, in cultures that place a high value on women's beauty, changes in appearance due to tightening of the skin on the face and other areas of the body can lead to feelings of unattractiveness and can impede scleroderma patients in attracting sexual partners or prevent women from exhibiting confidence (2) . Moreover, many patients with SSc have significant limitations on exercise capacity with dyspnea, decreased stamina, and coughing that may interfere with certain sexual behaviours (2, 3 
Data analysis
As a measure of relative context, correlations between the FSFI and other measures were undertaken first. Specifically, the FSFI total score was correlated with the SF-36 scales as well as the two summary measures of PCS and MCS, age, and disease duration using Pearson product-moment correlations. Additionally, Differences on the FSFI total score were examined between diffuse and limited SSc patients using a t-test. Next, symptoms noted by SSc patients on the FSFS were examined. Any symptoms in the FSFS with at least 10% response rate were flagged for examination. Specifically, mean differences on the FSFI were examined for any flagged FSFS symptom between those that indicated the symptom and those that did not. Analyses were conducted with t tests and effect sizes (Cohen's d) were also examined. Control for alpha was conducted using Tukey's (17) control for correlated outcomes with an unknown correlation, in order to provide appropriate control of Type I error. Please note that the Tukey process has been found to be more accurate in its control of alpha (18) than either Bonferroni (19) or Hochberg (20) .
Results
A total of 101 sets of questionnaires were completed. Sixty patients indicated they were sexually active (59.4%) and 41 patients cited no sexual activity (40.6%). The sexually inactive population was substantially older with a mean age of 55.9 years compared to a mean age of 47.5 years for the sexually active group. Reasons for sexual inactivity included lack of a partner (n=15, 36.6%), personal choice (n=13, 31.7%), and health status of the respondent's partner (n=8, 19.5%). Of note only 7 subjects (17%) cited their scleroderma as the primary reason for sexual inactivity.
The FSFI is best adapted for use in a sexually active population therefore only data from those patients who reported sexual activity in the four weeks prior to completing the survey were used in the analyses regarding sexual dysfunction. The mean FSFI score in the sexually active population was 24.9 (SD=6.7, range=4.5-34.8). This is lower than the mean score of 30.5 (SD=5.29) reported in the FSFI validation study (21) : the difference is statistically significant (t=7.14, p<0.001) with a large effect size (Cohen's d=1.01).
Regarding the SF-36, mean Physical Component Score (PCS) in the current sample was 39.6 (SD=10.9) and mean Mental Component Score (MCS) was 47.7 (SD=12.8).
For the first planned statistical analysis, FSFI scores were correlated with SF-36 scores, age, and disease duration in order to identify which aspects of health status were related to sexual function (see Table I ). Sexual functioning was strongly and positively correlated with MCS (r=.54, p<.001) and the mental scales (MH, RE, SF, and VT). However, sexual functioning was relatively unrelated to PCS and the physical scales (PF, RP, GH, and P). Nonsignificant relationships were found between sexual functioning and age as well as between sexual functioning and disease duration. FSFI scores did not differ between patients with diffuse or limited scleroderma. This seems to confirm that physical health appears to be unrelated to sexual health in this study sample.
Although physical functioning (SF-36) was not correlated with sexual functioning, a number of scleroderma-related problems were identified by participants as contributing to sexual difficulties (Table II) . Fatigue, body pain, vaginal dryness, and vaginal discomfort were cited most often. In order to identify how specific scleroderma problems affected sexual function, those symptoms reported by ten or more patients were analyzed by comparing mean FSFI scores of patients reporting the problem with those who did not (see Table III ). The mean FSFI scores were significantly decreased for patients presenting with depression, Raynaud's phenomenon, vaginal dryness, or vaginal discomfort.
Although not identified through the general quality of life SF-36, scleroderma-related physical problems appear to impact sexual functioning.
Conclusions
Sexual dysfunction is a common problem in both men and women in the general population (22) . In a large cohort study included in the National Social Life Survey, Health, and Aging Project (NSHAP) the reported rate of sexual inactivity in the prior year was 13.6% (23) . The rate of sexual inactivity among SSc patient in the current study was much higher at 40.6%. Importantly, our study asked about sexual activity in the prior four weeks. Similar to the cohort study, sexually inactive female scleroderma patients were more likely to be older, report emotional or stressrelated problems, and were more likely to report dysfunction in several areas of sexual functioning. Our findings suggest that scleroderma patients are similar to women in the general population in that sexual dysfunction is common and is strongly associated with psychosocial health (23, 24) . Similar findings have also been reported in studies on sexual function in other rheumatic diseases such as fibromyalgia where depression was the only covariate associated with sexual dysfunction in multivariate analysis (25) . Although our findings suggest that emotional health plays an important role in sexual functioning, we also observed that women with SSc have diseasespecific physical symptoms which may further impair their sexual functioning. Previous studies in chronic diseases such as RA and diabetes indicated that women with these diseases often experience sexual dysfunction due to pain, fatigue, and mechanical difficulties (26, 27) . Similarly, based on self assessment, scleroderma patients in this study identified common SSc physical symptoms which they believed adversely affected their sexual functioning. Raynaud's phenomenon, hand pain, vaginal dryness and discomfort, and fatigue, were physical findings that correlated with decreased sexual functioning. In addition to the emotional and psychological burden that SSc 
